ROSELLA / GOG-3073
Blocking cortisol signalling in tumour cells made chemotherapy work better and extended life in resistant ovarian cancer.
PFS 6.5 vs 5.5 months (HR 0.70) and OS 16.0 vs 11.9 months (HR 0.69; Lancet 2025). First-in-class glucocorticoid receptor antagonist; FDA approval in Q1 2026 as Lifyorli. Notable as a chemosensitisation mechanism rather than a new cytotoxic.
Setting
Platinum-resistant ovarian cancer, 1-3 prior lines: relacorilant + nab-paclitaxel vs nab-paclitaxel
Phase
Phase 3
Sponsor
Corcept
Registry
Headline result
OS 16.0 vs 11.9 months (HR 0.69).
Reported
2025
Enrolled
381
In plain words
What these results mean for people, not percentages
Progression-free survivalprimarysurrogate endpoint
- Median 6.5 vs 5.5 months with Relacorilant + nab-paclitaxel compared with Nab-paclitaxel; about 1 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 30 percent lower chance of the event at any given time (hazard ratio 0.7, likely range 0.54 to 0.91).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
Overall survivalsurvival endpoint
- Median 16 vs 11.9 months with Relacorilant + nab-paclitaxel compared with Nab-paclitaxel; about 4.1 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 31 percent lower chance of the event at any given time (hazard ratio 0.69).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
Be careful
- These results apply to the people the trial enrolled: Platinum-resistant ovarian cancer, 1-3 prior lines: relacorilant + nab-paclitaxel vs nab-paclitaxel. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
381 participants enrolled.
Progression-free survivalprimary
HR 0.7 (0.54–0.91)
Relacorilant + nab-paclitaxel
6.5 mo
Nab-paclitaxel
5.5 mo